Frontier Dispatch: Deep Tech Conversations
The conversation covers the development of novel neurotherapeutics by Xylo, the motivation and impact behind the work, Xylo's unfair advantage, Zoma Labs' continuous glucose monitoring, their unfair advantage, and Currus Biologics' cell therapy for solid tumors. Hosted by Elaine Stead.
4 episodes
Comments
0Be the first to comment
Sign up now and become a member of the Frontier Dispatch: Deep Tech Conversations community!